SPRY
ARS Pharmaceuticals Inc.
$8.58
+$0.41(+5.02%)
40
Overall
50
Value
36
Tech
34
Quality
Market Cap
$888.65M
Volume
221.69K
52W Range
$6.66 - $18.90
Target Price
$23.75
Company Overview
| Mkt Cap | $888.65M | Price | $8.58 |
| Volume | 221.69K | Change | +5.02% |
| P/E Ratio | -5.2 | Open | $8.22 |
| Revenue | $84.3M | Prev Close | $8.17 |
| Net Income | $-171.3M | 52W Range | $6.66 - $18.90 |
| Div Yield | N/A | Target | $23.75 |
| Overall | 40 | Value | 50 |
| Quality | 34 | Technical | 36 |
No chart data available
About ARS Pharmaceuticals Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Latest News
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks
TipRanks Auto-Generated Newsdesk•9 days ago
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY)
Catie Powers•12 days ago
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion
TipRanks Auto-Generated Newsdesk•12 days ago
ARS Pharmaceuticals Appoints Donn Casale as New President
TipRanks Auto-Generated Newsdesk•14 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRY | $8.58 | +5.0% | 221.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ARS Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW